Proteome Science · 2014 · 61 citations · 47 references
MedicineBiochemistryOncologyMolecular OncologyNeuro-oncologyProteomicsBiomarker ValidationCancer BiomarkersCancer ProteomicsMass Spectrometry-based ProteomicsProteomic BiomarkersProteomic ProfilingBiomarker PanelsBiomarkersCancer Proteome ProfilingDiagnostic BiomarkersGlioblastoma BiomarkersSerum BiomarkersSerum ProteomicsTumor Proteome Profiling
BACKGROUND: The rapid progress of proteomics over the past years has allowed the discovery of a large number of potential biomarker candidates to improve early tumor diagnosis and therapeutic response, thus being further integrated into clinical environment. High grade gliomas represent one of the most aggressive and treatment-resistant types of human brain cancer, with approximately 9-12 months median survival rate for patients with grade IV glioma (glioblastoma). Using state-of-the-art proteomics technologies, we have investigated the proteome profile for glioblastoma patients in order to identify a novel protein biomarker panel that could discriminate glioblastoma patients from controls and increase diagnostic accuracy. RESULTS: In this study, SELDI-ToF MS technology was used to screen potential protein patterns in glioblastoma patients serum; furthermore, LC-MS/MS technology was applied to identify the candidate biomarkers peaks. Through these proteomic approaches, three proteins S100A8, S100A9 and CXCL4 were selected as putative biomarkers and confirmed by ELISA. Next step was to validate the above mentioned molecules as biomarkers through identification of protein expression by Western blot in tumoral versus peritumoral tissue. CONCLUSIONS: Proteomic technologies have been used to investigate the protein profile of glioblastoma patients and established several potential diagnostic biomarkers. While it is unlikely for a single biomarker to be highly effective for glioblastoma diagnostic, our data proposed an alternative and efficient approach by using a novel combination of multiple biomarkers.
47
Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells
Pratima Sinha, Chinonyerem Okoro, Dirk Foell et al. · The Journal of Immunology · 2008 · 725 citations · Full text
Medicine, Immunology, Oncology +17
Martin J. van den Bent, Hendrikus J. Dubbink, Yannick Marie et al. · Clinical Cancer Research · 2010 · 381 citations
Medicine, Oncology, Pharmacology +15
Involvement of platelets in tumour angiogenesis?
HM Pinedo, RJ D'Amato, Judah Folkman · The Lancet · 1998 · 362 citations
Medicine, Hematology, Oncology +12
VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients
Jon E. Peterson, David Zurakowski, Joseph E. Italiano et al. · Angiogenesis · 2012 · 235 citations
Medicine, Hematology, Oncology +12